S&P 500   4,274.04 (-0.72%)
DOW   33,980.32 (-0.50%)
QQQ   328.76 (-1.06%)
AAPL   174.77 (+1.01%)
MSFT   291.33 (-0.47%)
META   174.65 (-2.69%)
GOOGL   119.55 (-1.77%)
AMZN   142.08 (-1.86%)
TSLA   911.62 (-0.88%)
NVDA   183.48 (-2.81%)
NIO   20.10 (-3.87%)
BABA   89.77 (-3.11%)
AMD   98.30 (-1.90%)
MU   61.61 (-3.52%)
T   18.43 (-0.75%)
CGC   4.07 (+7.67%)
F   16.04 (-2.37%)
GE   79.89 (-1.46%)
DIS   122.79 (-1.74%)
AMC   21.11 (-14.91%)
PYPL   99.39 (-2.64%)
PFE   49.27 (-1.18%)
NFLX   241.03 (-1.90%)
S&P 500   4,274.04 (-0.72%)
DOW   33,980.32 (-0.50%)
QQQ   328.76 (-1.06%)
AAPL   174.77 (+1.01%)
MSFT   291.33 (-0.47%)
META   174.65 (-2.69%)
GOOGL   119.55 (-1.77%)
AMZN   142.08 (-1.86%)
TSLA   911.62 (-0.88%)
NVDA   183.48 (-2.81%)
NIO   20.10 (-3.87%)
BABA   89.77 (-3.11%)
AMD   98.30 (-1.90%)
MU   61.61 (-3.52%)
T   18.43 (-0.75%)
CGC   4.07 (+7.67%)
F   16.04 (-2.37%)
GE   79.89 (-1.46%)
DIS   122.79 (-1.74%)
AMC   21.11 (-14.91%)
PYPL   99.39 (-2.64%)
PFE   49.27 (-1.18%)
NFLX   241.03 (-1.90%)
S&P 500   4,274.04 (-0.72%)
DOW   33,980.32 (-0.50%)
QQQ   328.76 (-1.06%)
AAPL   174.77 (+1.01%)
MSFT   291.33 (-0.47%)
META   174.65 (-2.69%)
GOOGL   119.55 (-1.77%)
AMZN   142.08 (-1.86%)
TSLA   911.62 (-0.88%)
NVDA   183.48 (-2.81%)
NIO   20.10 (-3.87%)
BABA   89.77 (-3.11%)
AMD   98.30 (-1.90%)
MU   61.61 (-3.52%)
T   18.43 (-0.75%)
CGC   4.07 (+7.67%)
F   16.04 (-2.37%)
GE   79.89 (-1.46%)
DIS   122.79 (-1.74%)
AMC   21.11 (-14.91%)
PYPL   99.39 (-2.64%)
PFE   49.27 (-1.18%)
NFLX   241.03 (-1.90%)
S&P 500   4,274.04 (-0.72%)
DOW   33,980.32 (-0.50%)
QQQ   328.76 (-1.06%)
AAPL   174.77 (+1.01%)
MSFT   291.33 (-0.47%)
META   174.65 (-2.69%)
GOOGL   119.55 (-1.77%)
AMZN   142.08 (-1.86%)
TSLA   911.62 (-0.88%)
NVDA   183.48 (-2.81%)
NIO   20.10 (-3.87%)
BABA   89.77 (-3.11%)
AMD   98.30 (-1.90%)
MU   61.61 (-3.52%)
T   18.43 (-0.75%)
CGC   4.07 (+7.67%)
F   16.04 (-2.37%)
GE   79.89 (-1.46%)
DIS   122.79 (-1.74%)
AMC   21.11 (-14.91%)
PYPL   99.39 (-2.64%)
PFE   49.27 (-1.18%)
NFLX   241.03 (-1.90%)
NASDAQ:OBSV

ObsEva - OBSV Stock Forecast, Price & News

$0.25
-0.01 (-4.55%)
(As of 08/17/2022 03:59 PM ET)
Add
Compare
Today's Range
$0.24
$0.27
50-Day Range
$0.22
$2.07
52-Week Range
$0.22
$3.35
Volume
254,348 shs
Average Volume
4.99 million shs
Market Capitalization
$19.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50

ObsEva MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
4,185.7% Upside
$10.50 Price Target
Short Interest
Healthy
4.47% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.91mentions of ObsEva in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.75) to ($0.65) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Medical Sector

325th out of 1,122 stocks

Pharmaceutical Preparations Industry

154th out of 551 stocks

OBSV stock logo

About ObsEva (NASDAQ:OBSV) Stock

ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.

ObsEva Stock Performance

Shares of NASDAQ:OBSV opened at $0.26 on Wednesday. The company has a market capitalization of $20.58 million, a P/E ratio of -0.41 and a beta of 0.21. The business's 50-day moving average price is $1.31 and its two-hundred day moving average price is $1.41. ObsEva has a one year low of $0.22 and a one year high of $3.35. The company has a debt-to-equity ratio of 1.18, a current ratio of 3.09 and a quick ratio of 3.09.

ObsEva (NASDAQ:OBSV - Get Rating) last released its quarterly earnings results on Tuesday, May 17th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.11. The company had revenue of $2.24 million for the quarter. Analysts anticipate that ObsEva will post -0.75 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. StockNews.com assumed coverage on ObsEva in a research report on Saturday. They set a "hold" rating for the company. Canaccord Genuity Group downgraded ObsEva from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $12.00 to $1.00 in a research note on Monday, August 1st. Canaccord Genuity Group assumed coverage on ObsEva in a research note on Tuesday, April 26th. They issued a "buy" rating and a $12.00 price objective on the stock. Cantor Fitzgerald lowered ObsEva from an "overweight" rating to a "neutral" rating in a research report on Thursday, July 28th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $11.00 target price on shares of ObsEva in a research report on Tuesday, June 21st. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $10.50.

Receive OBSV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ObsEva and its competitors with MarketBeat's FREE daily newsletter.

OBSV Stock News Headlines

ObsEva (NASDAQ:OBSV) Coverage Initiated at StockNews.com
Short Interest in ObsEva SA (NASDAQ:OBSV) Drops By 19.6%
How High Can Copper Go?
To power the green revolution, copper demand continues to skyrocket with no end in sight. Prices hit a 10-year high; as copper jumped 79% in the past year. Some analysts are calling for copper to rise another 50-100%! We may be at the beginning of a copper bull run the likes we've never seen before. Just how high can copper go?
ObsEva SA (NASDAQ:OBSV) Sees Large Decrease in Short Interest
ObsEva (NASDAQ:OBSV) Now Covered by StockNews.com
How High Can Copper Go?
To power the green revolution, copper demand continues to skyrocket with no end in sight. Prices hit a 10-year high; as copper jumped 79% in the past year. Some analysts are calling for copper to rise another 50-100%! We may be at the beginning of a copper bull run the likes we've never seen before. Just how high can copper go?
ObsEva Announces Corporate Updates - Yahoo Finance
See More Headlines
Receive OBSV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ObsEva and its competitors with MarketBeat's FREE daily newsletter.

OBSV Company Calendar

Last Earnings
11/04/2021
Today
8/17/2022
Next Earnings (Estimated)
8/18/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OBSV
Fax
N/A
Employees
48
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.50
High Stock Price Forecast
$21.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+4,066.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$-58,380,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$20.11 million
Book Value
$0.41 per share

Miscellaneous

Free Float
N/A
Market Cap
$19.65 million
Optionable
Not Optionable
Beta
0.20

Key Executives

  • Mr. Brian O'Callaghan (Age 53)
    CEO & Director
    Comp: $1.12M
  • Dr. Ernest Loumaye M.D. (Age 70)
    OB/GYN, Ph.D., Co-Founder & Director
    Comp: $62k
  • Dr. Jean-Pierre Gotteland Ph.D. (Age 57)
    Chief Scientific Officer and Head of R&D
  • Mr. Fabien Lefebvre de Ladonchamps (Age 43)
    Chief Admin. Officer
  • Mr. Clive Bertram (Age 54)
    Chief Commercial Officer
  • Mr. Luigi Marro (Age 56)
    Chief Transformation Officer
  • Mr. William Michael Brown (Age 39)
    Chief Financial Officer
  • Ms. Delphine Renaud
    Personal Assistant to the CSO and Head of R&D
  • Ms. Katja Buhrer (Age 40)
    Chief Strategy Officer
  • Ms. Brandi Howard Ph.D.
    Chief Clinical Officer













OBSV Stock - Frequently Asked Questions

Should I buy or sell ObsEva stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ObsEva in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OBSV shares.
View OBSV analyst ratings
or view top-rated stocks.

What is ObsEva's stock price forecast for 2022?

6 equities research analysts have issued 12 month price objectives for ObsEva's stock. Their OBSV share price forecasts range from $1.00 to $21.00. On average, they predict the company's share price to reach $10.50 in the next year. This suggests a possible upside of 3,877.3% from the stock's current price.
View analysts price targets for OBSV
or view top-rated stocks among Wall Street analysts.

How have OBSV shares performed in 2022?

ObsEva's stock was trading at $1.99 at the start of the year. Since then, OBSV shares have decreased by 86.7% and is now trading at $0.2640.
View the best growth stocks for 2022 here
.

When is ObsEva's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 18th 2022.
View our OBSV earnings forecast
.

How were ObsEva's earnings last quarter?

ObsEva SA (NASDAQ:OBSV) posted its quarterly earnings results on Thursday, November, 4th. The company reported $0.01 earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.23.

What other stocks do shareholders of ObsEva own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ObsEva investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Trevena (TRVN), Zosano Pharma (ZSAN), Vaxart (VXRT), VBI Vaccines (VBIV), Bionano Genomics (BNGO) and ADMA Biologics (ADMA).

When did ObsEva IPO?

(OBSV) raised $98 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 6,500,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.

What is ObsEva's stock symbol?

ObsEva trades on the NASDAQ under the ticker symbol "OBSV."

Who are ObsEva's major shareholders?

ObsEva's stock is owned by a variety of retail and institutional investors. Top institutional investors include Credit Suisse AG (1.86%), Pictet Asset Management SA (0.38%), Millennium Management LLC (0.15%), Virtu Financial LLC (0.13%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of ObsEva?

Shares of OBSV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ObsEva's stock price today?

One share of OBSV stock can currently be purchased for approximately $0.26.

How much money does ObsEva make?

ObsEva (NASDAQ:OBSV) has a market capitalization of $20.58 million and generates $20.11 million in revenue each year. The company earns $-58,380,000.00 in net income (profit) each year or ($0.64) on an earnings per share basis.

How can I contact ObsEva?

ObsEva's mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The official website for the company is www.obseva.com. The company can be reached via phone at (122) 552-3840 or via email at ir@obseva.ch.

This page (NASDAQ:OBSV) was last updated on 8/17/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.